Sarah Gregory

Sarah Gregory

Auto-generated profile, based on publicly available information

Sarah Gregory

Huntington's Disease Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
SGSarah Gregory
Sarah Gregory
DFDominic Ffytche
Dominic Ffytche
ASAndrew Simmons
Andrew Simmons
VKVeena Kumari
Veena Kumari
MHMatthew Howard
Matthew Howard
NBNigel Blackwood
Nigel Blackwood
Violence is a global public health problem.1 Most violent crimes are committed by a small group of life-course-persistent male offenders, who meet diagnostic criteria for conduct disorder as children and antisocial personality disorder (ASPD) as adults.2-4 Behavioral genetic research suggests that such stable antisocial behavior is moderately heritable.5,6

1 June 2020 in The Lancet Neurology
Verified
Journal Article
Open access
RSRachael Scahill
Rachael Scahill
PZPaul Zeun
Paul Zeun
KOKatherine Osborne-Crowley
Katherine Osborne-Crowley
EJEileanoir B Johnson
Eileanoir B Johnson
SGSarah Gregory
Sarah Gregory
STSarah J Tabrizi
Sarah J Tabrizi
Disease-modifying treatments are in development for Huntington's disease; crucial to their success is to identify a timepoint in a patient's life when there is a measurable biomarker of early neurodegeneration while clinical function is still intact. We aimed to identify this timepoint in a novel cohort of young adult premanifest Huntington's disease gene carriers (preHD) far from predicted clinical symptom onset. We did the Huntington's disease Young Adult Study (HD-YAS) in the UK. We recruited young adults with preHD and controls matched for age, education, and sex to ensure each group had at least 60 participants with imaging data, accounting for scan fails. Controls either had a family history of Huntington's disease but a negative genetic test, or no known family history of Huntington's disease. All participants underwent detailed neuropsychiatric and cognitive assessments, including tests from the Cambridge Neuropsychological Test Automated Battery and a battery assessing emotion, motivation, impulsivity and social cognition (EMOTICOM). Imaging (done for all participants without contraindications) included volumetric MRI, diffusion imaging, and multiparametric mapping. Biofluid markers of neuronal health were examined using blood and CSF collection. We did a cross-sectional analysis using general least-squares linear models to assess group differences and associations with age and CAG length, relating to predicted years to clinical onset. Results were corrected for multiple comparisons using the false discovery rate (FDR), with FDR 0·16). CSF neurofilament light protein (NfL), plasma NfL, and CSF YKL-40 were elevated in this far-from-onset preHD cohort compared with controls (FDR<0·0001, =0·01, and =0·03, respectively). CSF NfL elevations were more likely in individuals closer to expected clinical onset (FDR <0·0001). We report normal brain function yet a rise in sensitive measures of neurodegeneration in a preHD cohort approximately 24 years from predicted clinical onset. CSF NfL appears to be a more sensitive measure than plasma NfL to monitor disease progression. This preHD cohort is one of the earliest yet studied, and our findings could be used to inform decisions about when to initiate a potential future intervention to delay or prevent further neurodegeneration while function is intact. Wellcome Trust, CHDI Foundation.

1 October 2015 in EBioMedicine
Verified
Journal Article
Open access
SKStefan Klöppel
Stefan Klöppel
SGSarah Gregory
Sarah Gregory
ESElisa Scheller
Elisa Scheller
LMLora Minkova
Lora Minkova
Razi AdeelRazi Adeel
Razi Adeel
STSarah J. Tabrizi
Sarah J. Tabrizi
Cognitive and motor task performance in premanifest Huntington's disease (HD) gene-carriers is often within normal ranges prior to clinical diagnosis, despite loss of brain volume in regions involved in these tasks. This indicates ongoing compensation, with the brain maintaining function in the presence of neuronal loss. However, thus far, compensatory processes in HD have not been modeled explicitly. Using a new model, which incorporates individual variability related to structural change and behavior, we sought to identify functional correlates of compensation in premanifest-HD gene-carriers. We investigated the modulatory effects of regional brain atrophy, indexed by structural measures of disease load, on the relationship between performance and brain activity (or connectivity) using task-based and resting-state functional MRI. Consistent with compensation, as atrophy increased performance-related activity increased in the right parietal cortex during a working memory task. Similarly, increased functional coupling between the right dorsolateral prefrontal cortex and a left hemisphere network in the resting-state predicted better cognitive performance as atrophy increased. Such patterns were not detectable for the left hemisphere or for motor tasks. Our findings provide evidence for active compensatory processes in premanifest-HD for cognitive demands and suggest a higher vulnerability of the left hemisphere to the effects of regional atrophy.

17 September 2015 in Brain
Verified
Journal Article
Open access
PDF file
PMPeter McColgan
Peter McColgan
KSKiran K. Seunarine
Kiran K. Seunarine
Razi AdeelRazi Adeel
Razi Adeel
JCJames H. Cole
James H. Cole
SGSarah Gregory
Sarah Gregory
STSarah J. Tabrizi
Sarah J. Tabrizi
Huntington’s disease can be predicted many years before symptom onset, and thus makes an ideal model for studying the earliest mechanisms of neurodegeneration. Diffuse patterns of structural connectivity loss occur in the basal ganglia and cortex early in the disease. However, the organizational principles that underlie these changes are unclear. By understanding such principles we can gain insight into the link between the cellular pathology caused by mutant huntingtin and its downstream effect at the macroscopic level. The ‘rich club’ is a pattern of organization established in healthy human brains, where specific hub ‘rich club’ brain regions are more highly connected to each other than other brain regions. We hypothesized that selective loss of rich club connectivity might represent an organizing principle underlying the distributed pattern of structural connectivity loss seen in Huntington’s disease. To test this hypothesis we performed diffusion tractography and graph theoretical analysis in a pseudo-longitudinal study of 50 premanifest and 38 manifest Huntington’s disease participants compared with 47 healthy controls. Consistent with our hypothesis we found that structural connectivity loss selectively affected rich club brain regions in premanifest and manifest Huntington’s disease participants compared with controls. We found progressive network changes across controls, premanifest Huntington’s disease and manifest Huntington’s disease characterized by increased network segregation in the premanifest stage and loss of network integration in manifest disease. These regional and whole brain network differences were highly correlated with cognitive and motor deficits suggesting they have pathophysiological relevance. We also observed greater reductions in the connectivity of brain regions that have higher network traffic and lower clustering of neighbouring regions. This provides a potential mechanism that results in a characteristic pattern of structural connectivity loss targeting highly connected brain regions with high network traffic and low clustering of neighbouring regions. Our findings highlight the role of the rich club as a substrate for the structural connectivity loss seen in Huntington’s disease and have broader implications for understanding the connection between molecular and systems level pathology in neurodegenerative disease.

1 February 2015 in The Lancet Psychiatry
Verified
Journal Article
Closed access
SGSarah Gregory
Sarah Gregory
RBR James Blair
R James Blair
DFDominic Ffytche
Dominic Ffytche
ASAndrew Simmons
Andrew Simmons
VKVeena Kumari
Veena Kumari
NBNigel Blackwood
Nigel Blackwood

23 February 2017 in Brain
Verified
Journal Article
Open access
PDF file
SGSarah Gregory
Sarah Gregory
JLJeffrey D. Long
Jeffrey D. Long
SKStefan Klöppel
Stefan Klöppel
Razi AdeelRazi Adeel
Razi Adeel
ESElisa Scheller
Elisa Scheller
GRGeraint Rees
Geraint Rees
Neuronal compensation is widely assumed to account for the dissociation between brain pathology and (absence of) behavioural change during the prodromal and early stages of neurodegenerative conditions such as Huntington’s disease and Alzheimer’s disease ( Barulli and Stern, 2013; Dennis and Cabeza, 2013; Scheller et al., 2014). Despite varying degrees of structural loss, patients demonstrate a level of performance during many tasks that is indistinguishable from their earlier performance, and is often similar to that of a normal population ( Obeso et al., 2004; Malejko et al., 2014; Papoutsi et al., 2014; Kloppel and Gregory, 2015). Performance is maintained until pathological factors progress and performance levels begin to deteriorate. However, neuronal mechanisms that underlie such postulated compensation in neurodegeneration are poorly understood due to the complexity in defining what compensation actually is and how it can be measured.